SELLAS Life Sciences (SLS) Accumulated Expenses (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Accumulated Expenses data on file, last reported at $2.3 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.3 million, down 12.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (down 12.06% YoY), and the FY2025 annual result was $3.5 million, down 35.51% from the prior year.
• Accumulated Expenses retreated to $2.3 million in Q1 2026 per SLS's latest filing, from $3.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $7.6 million in Q4 2023 and troughed at $2.1 million in Q2 2025.
• A 5-year average of $4.7 million and a median of $5.2 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses jumped 138.11% in 2022, then slumped 60.7% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $6.3 million in 2022, then grew by 21.7% to $7.6 million in 2023, then slipped by 28.55% to $5.5 million in 2024, then tumbled by 35.51% to $3.5 million in 2025, then sank by 35.86% to $2.3 million in 2026.
• Business Quant data shows SLS's Accumulated Expenses at $2.3 million in Q1 2026, $3.5 million in Q4 2025, and $3.0 million in Q3 2025.